ABT-866

ABT-866 is an α1A-adrenoceptor agonist and an antagonist at the α1B- and α1D-adrenoceptor subtypes. ABT-866 has an EC50 of 0.60 μM for the α1A in the rabbit urethra. ABT-866 has a pA2 value of 5.4 for the α1B in the rat spleen. ABT-866 has a pA2 value of 6.2 for the α1D in the rat aorta. ABT-866 exhibits good urethral selectivity and lower cardiovascular side effects in stress urinary incontinence models. ABT-866 can be used for the research of diseases such as stress urinary incontinence[1][2].

Product Specifications

CAS Number

[258526-74-8]

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Adrenergic Receptor

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Endocrinology; Cardiovascular Disease

Smiles

O=S(NC1=CC=CC(CC2=CN=CN2)=C1)(CC)=O

Molecular Formula

C12H15N3O2S

Molecular Weight

265.33

Precautions

P261-P280-P302+P352

References & Citations

[1]Buckner SA, et al. ABT-866, a novel alpha (1A) -adrenoceptor agonist with antagonist properties at the alpha (1B) - and alpha (1D) -adrenoceptor subtypes. Eur J Pharmacol. 2002 Aug 2;449 (1-2) :159-65.|[2]Altenbach RJ, et al. N-[3- (1H-imidazol-4-ylmethyl) phenyl]ethanesulfonamide (ABT-866, 1), (1) a novel alpha (1) -adrenoceptor ligand with an enhanced in vitro and in vivo profile relative to phenylpropanolamine and midodrine. J Med Chem. 2002 Sep 26;45 (20) :4395-7.